text.skipToContent text.skipToNavigation
Need help? Please contact us

You searched for "CD34%2B cells%3A%3A%3A%3A"

588 Products found
Too many choices? Use the filter option on the left to narrow your product listing.
  • 1(current)
  • 2
  • 3

You searched for "CD34%2B cells%3A%3A%3A%3A"

1,009 Documents found
  • A Non-Viral Method for Modifying and Expanding Primary T Cells
    Learn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.
  • Instructions – PPiLight™ Inorganic Pyrophosphate Assay Kit
    Instructions for proper use of PPiLight™ Inorganic Pyrophosphate Assay Kit
  • The Efficiency and Accuracy of Automated Endotoxin Testing and Process Optimization
    Full Title:   Streamlining Your QC Testing: The Efficiency and Accuracy of Automated Endotoxin Testing and Process Optimization
  • Expanded HUVECs for High-throughput Screening
    HUVECs are a good primary endothelial cell type for many in vitro studies and also for several high-throughput screening applications. Consequently, Lonza offers, HUVEC-XL. These cells are expanded to passage-3 from pooled P1-HUVECs and packaged at 10 million cells per ampoule.
  • Cold Storage of Fresh Leukopak Maintains Cell Viability and Functionality
    Learn how advanced cold storage approaches enable optimal levels of product integrity, quality, stability and viability
  • A 3D Bioprinted Model to Study Osteogenic Differentiation of Primary Mesenchymal Stem Cells
    Learn from this white paper how a 3D bioprinted model using hMSCs can be used for evaluation of bioink compatibility and bioprinting processes.
  • Terms and Conditions
    CD34+ cells BOGO
  • B-ALI Bronchial Air Liquid Interface Media Kit, a Guaranteed 3D in vitro Model for Respiratory Research
    Lonza Whitepaper
  • B-ALI Bronchial Air Liquid Interface Media Kit, a Guaranteed 3D in vitro Model for Respiratory Research
    CD-SP095_BALI-Bronchial-Air Liquid-Interface_sec.pdf
  • eBook by The Scientist and Lonza: Primary Cells in Research
    An ebook produced in conjunction with The Scientist highlighting Primary Cells, Primary Cell Culture Process, In Vitro, and Relevant In Vitro Models.
  • Primary Human Umbilical Vein Endothelial Cells
    Tech note demonstrating the successful development of tube formation assay using primary HUVECs that can be used to visualize angiogenesis in real-time.
  • Transfection Protocol for Human CD34+ Cells - Nucleofector™ I/II/2b Device Series
    Instructions of use for transfection of human CD34+ cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
  • NK Cell Assay using 3D Bioprinted Tumor Models
    This white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
  • Synthego-Lonza Genome Editing of Resting T cells
    Case Study on Genome Editing of Resting T cells
  • Automated Cell Signaling Assays Using Primary HUVECs
    Lonza's Primary HUVECs are an excellent cell type to measure the effects of pharmacologically-important compounds on vial signaling pathways, and they provide increased data relevancy compared to cell lines.
  • 3D Natural Killer Cell-mediated Cytotoxicity Assay
    Lonza White Paper
  • First siRNA Library Screening in Hard-to-Transfect HUVEC and Jurkat Cells
    High throughput transfection of siRNA libraries has become a valuable tool in target identifi cation and validation. However, such screenings have so far been constrained to mostly easy-totransfect adherent cell lines. Lonza’s 96-well Shuttle® System, based on the well-established Amaxa® Nucleofector® Technology, extends these approaches to primary and diffi cult-to-transfect cells.
  • Instructions and Technical Sheet- Human CD34+ Cells
  • Efficient Transfection of Cancer Cell Lines Using the 4D-Nucleofector™ System
    Product data sheet showing efficient tranfection of cancer cell lines
  • Mitosis of CD34+ cells with Nanolive's 3D Cell Explorer
  • 1(current)
  • 2
  • 3